SCHEMBL22916971

SCHEMBL22916971

CC(=O)N[C@H]1C[C@H](NC(=O)C(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.48
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 1/20 0.46
CCNT1 O60563 1/20 0.36
CDK1 P06493 1/20 0.36
CDK4 P11802 1/20 0.36
CCNA2 P20248 1/20 0.36
CCND1 P24385 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
CCNA1 P78396 1/20 0.36
CDK3 Q00526 1/20 0.36
FASN P49327 1/20 0.35
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35
TLR4 O00206 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20987777 0.88 ALDH1A1 (0.49) ATMALDH1A1KDM4EFASNMTNR1A
SCHEMBL18880058 0.87 ATM (0.44) ATMALDH1A1KDM4EFASNMTNR1A
SCHEMBL13165905 0.83 ATM (0.62) ATMALDH1A1KDM4ECCNT1CDK1
SCHEMBL1900325 0.83 ATM (0.62) ATMALDH1A1KDM4ECCNT1CDK1
SCHEMBL21424044 0.83 ATM (0.62) ATMALDH1A1KDM4ECCNT1CDK1
SCHEMBL12206769 0.80 FASN (0.36) ATMFASNMTNR1AMTNR1B
SCHEMBL16252563 0.80 FASN (0.36) ATMFASNMTNR1AMTNR1B
SCHEMBL15199663 0.80 FASN (0.36) ATMALDH1A1FASNMTNR1AMTNR1B
SCHEMBL13035557 0.80 EPHX2 (0.41) ALDH1A1FASNMTNR1AMTNR1B
SCHEMBL12207205 0.80 FASN (0.36) ATMFASNMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
EP-3778573-A1 COMPOUND WITH ANTICANCER ACTIVITY Kyowa Kirin Co., Ltd. (JP) 2021-02-17 EP disclosed
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 ATM 1678/4885ALDH1A1 199/4885KDM4E 4107/4885
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 ATM 1678/4885ALDH1A1 199/4885KDM4E 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.